Optiver Holding
ZVRA icon

Optiver Holding’s Zevra Therapeutics ZVRA Stock Holding History

Optiver Holding’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-149
Closed -$1.39K – 3136
2026
Q1 		$1.39K Buy
+149
New +$1.34K ﹤0.01% 1984
2025
Q4 		– Sell
-386
Closed -$3.67K – 3083
2025
Q3 		$3.67K Buy
+386
New +$3.87K ﹤0.01% 2031

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Optiver Holding's ZVRA Position: Q2 2026 in Review

Optiver Holding sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 149 shares — an estimated $1.39K sold.

Optiver Holding first reported a position in ZVRA in Q3 2025 and held it in 2 quarters. The position peaked at $3.67K in Q3 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Optiver Holding reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Optiver Holding sold 149 Zevra Therapeutics shares in Q2 2026, an estimated $1.39K.
  • Optiver Holding first reported a position in Zevra Therapeutics in Q3 2025 and held it in 2 quarters.
  • Optiver Holding's Zevra Therapeutics position peaked at $3.67K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.